Search Results - "Nielsen, Tina G."

Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma by Kim, Eugene, Jiang, Yanwen, Xu, Tao, Bazeos, Alexandra, Knapp, Andrea, Bolen, Christopher R, Humphrey, Kathryn, Nielsen, Tina G, Penuel, Elicia, Paulson, Joseph N

“…Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease defined using a number of well-established molecular subsets. Application of non-negative…”
Get full text

Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM by Wong, Sandy, Hamidi, Habib, Costa, Luciano J, Bekri, Selma, Neparidze, Natalia, Vij, Ravi, Nielsen, Tina G, Raval, Aparna, Sareen, Rajan, Wassner-Fritsch, Elisabeth, Cho, Hearn J

“…Multiple myeloma (MM) remains incurable, and treatment of relapsed/refractory (R/R) disease is challenging. There is an unmet need for more targeted therapies…”
Get full text

Overview of the human pharmacokinetics of recombinant activated factor VII by Klitgaard, Thomas, Nielsen, Tina G.

“…AIMS To review the pharmacokinetics of rFVIIa in various patient populations, and to discuss the differences observed between groups. METHODS Based on a…”
Get full text

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial by Herold, Michael, Hoster, Eva, Janssens, Ann, McCarthy, Helen, Tedeschi, Alessandra, Pocock, Chris, Rosta, Andras, Trněný, Marek, Nielsen, Tina G., Knapp, Andrea, Hiddemann, Wolfgang, Marcus, Robert

“…The aim of this study was to explore the efficacy and safety of obinutuzumab (G)‐ versus rituximab (R)‐chemotherapy in a subgroup of patients with previously…”
Get full text

A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials by Kostakoglu, Lale, Martelli, Maurizio, Sehn, Laurie H, Davies, Andrew, Trněný, Marek, Herold, Michael, Vitolo, Umberto, Hiddemann, Wolfgang, Trotman, Judith, Knapp, Andrea, Mattiello, Federico, Nielsen, Tina G, Sahin, Deniz, Sellam, Gila, Ward, Carol, Younes, Anas

“…The Lugano 2014 criteria are the standard for response assessment in lymphoma. We compared the prognostic performance of Lugano 2014 and the more recently…”
Get full text

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study by Townsend, William, Hiddemann, Wolfgang, Buske, Christian, Cartron, Guillaume, Cunningham, David, Dyer, Martin J.S., Gribben, John G., Phillips, Elizabeth H., Dreyling, Martin, Seymour, John F., Grigg, Andrew, Trotman, Judith, Lin, Tong‐Yu, Hong, Xiao‐Nan, Kingbiel, Dirk, Nielsen, Tina G., Knapp, Andrea, Herold, Michael, Marcus, Robert

“…The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab‐based versus rituximab‐based immunochemotherapy in patients with previously…”
Get full text

A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA by Kostakoglu, Lale, Dalmasso, Federico, Berchialla, Paola, Pierce, Larry A., Vitolo, Umberto, Martelli, Maurizio, Sehn, Laurie H., Trněný, Marek, Nielsen, Tina G., Bolen, Christopher R., Sahin, Deniz, Lee, Calvin, El‐Galaly, Tarec Christoffer, Mattiello, Federico, Kinahan, Paul E., Chauvie, Stephane

“…Image texture analysis (radiomics) uses radiographic images to quantify characteristics that may identify tumour heterogeneity and associated patient outcomes…”
Get full text

Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study by Barrington, Sally F, Mir, Farheen, El-Galaly, Tarec Christoffer, Knapp, Andrea, Nielsen, Tina G, Sahin, Denis, Wenger, Michael, Kostakoglu, Lale, Trotman, Judith, Meignan, Michel

“…Complete metabolic response (CMR) on PET/CT was the sole independent predictor of overall survival in the PET substudy of the phase III GALLIUM trial…”
Get full text

NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL by Tabari, Ehsan, Lovejoy, Alexander F, Lin, Hai, Bolen, Christopher R, Lor Saelee, Seng, Lefkowitz, Joshua P, Kurtz, David M, Bottos, Alessia, Nielsen, Tina G, Parreira, Joana M, Luong, Khai T

“…Personalized risk stratification and treatment may help improve outcomes among patients with diffuse large B-cell lymphoma (DLBCL). We developed a…”
Get full text

Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA by Ruiz, Irene Canales, Martelli, Maurizio, Sehn, Laurie H., Vitolo, Umberto, Nielsen, Tina G., Sellam, Gila, Bottos, Alessia, Klingbiel, Dirk, Kostakoglu, Lale

“…A good response to initial therapy is key to maximizing survival in patients with diffuse large B-cell lymphoma (DLBCL), but patients with chemorefractory…”
Get full text

Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study by Casulo, Carla, Herold, Michael, Hiddemann, Wolfgang, Iyengar, Sunil, Marcus, Robert E., Seymour, John F., Launonen, Aino, Knapp, Andrea, Nielsen, Tina G., Mir, Farheen

“…Although advanced‑stage follicular lymphoma (FL) is considered incurable, survival has improved with the introduction of the anti-CD20 antibodies, rituximab…”
Get full text

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma by Topp, Max S., Eradat, Herbert, Florschütz, Axel, Hochhaus, Andreas, Wrobel, Tomasz, Walewski, Jan, Knopinska-Posluszny, Wanda, Kanate, Abraham S., Lech-Maranda, Ewa, Brunnberg, Uta, Chitra, Surya, Nielsen, Tina G., Sellam, Gila, Shivhare, Mahesh, Lossos, Izidore S.

“…Purpose New therapies are needed for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. This phase 1b, open-label trial evaluated two anti-CD20-based…”
Get full text

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia by Wierda, William G., Kipps, Thomas J., Dürig, Jan, Griskevicius, Laimonas, Stilgenbauer, Stephan, Mayer, Jiří, Smolej, Lukáš, Hess, Georg, Griniute, Rasa, Hernandez-Ilizaliturri, Francisco J., Padmanabhan, Swaminathan, Gorczyca, Michele, Chang, Chai-Ni, Chan, Geoffrey, Gupta, Ira, Nielsen, Tina G., Russell, Charlotte A.

“…We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab, a human CD20 mAb, combined with fludarabine and cyclophosphamide (O-FC) as…”
Get full text

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma by Younes, Anas, Burke, John M., Cheson, Bruce D., Diefenbach, Catherine S., Ferrari, Silvia, Hahn, Uwe H., Hawkes, Eliza A., Khan, Cyrus, Lossos, Izidore S., Musuraca, Gerardo, Tani, Monica, Vitolo, Umberto, Yuen, Sam, Raval, Aparna, Shivhare, Mahesh, Nielsen, Tina G., Sellam, Gila, Sharman, Jeff P.

“…•Atezo–R-CHOP appeared to improve CR rates compared with historical controls but not so much as to warrant further study.•The atezo–R-CHOP combination…”
Get full text

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma by Younes, Anas, Burke, John M., Diefenbach, Catherine, Ferrari, Silvia, Khan, Cyrus, Sharman, Jeff P., Tani, Monica, Ujjani, Chaitra, Vitolo, Umberto, Yuen, Sam, Raval, Aparna, Shivhare, Mahesh, Nielsen, Tina G., Sellam, Gila, Gilbertson, Michael

“…•The addition of atezolizumab to a G-bendamustine regimen does not appear to further improve PFS in patients with previously untreated FL.•The addition of…”
Get full text

Outcomes and costs of penetrating trauma injury in England and Wales by Christensen, Michael C, Nielsen, Tina G, Ridley, Saxon, Lecky, Fiona E, Morris, Stephen

“…Summary Background Penetrating trauma injury is generally associated with higher short-term mortality than blunt trauma, and results in substantial societal…”
Get full text

Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins by MOES GRØNHOLDT, M.-L, NORDESTGAARD, B. G, NIELSEN, T. G, SILLESEN, H

“…Echolucent carotid atherosclerotic plaques are associated with an increased risk of neurological symptoms. Elevated plasma triglycerides is a risk factor for…”
Get full text

TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma by Harris, Will, Bataillard, Edward J, Choi, Yoonha, El-Galaly, Tarec C, Cuchelkar, Vaikunth, Henneges, Carsten, Kwan, Antonia, Schneider, Daniel J, Paulson, Joseph N, Nielsen, Tina G

“…Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) represents the standard of care for first-line treatment of diffuse large…”
Get more information

Cost-Drivers in Acute Treatment of Severe Trauma in Europe: A Systematic Review of Literature by Pape, Hans-Christoph, Neugebauer, Edmund, Ridley, Saxon A., Chiara, Osvaldo, Nielsen, Tina G., Christensen, Michael C.

“…Introduction: Throughout the world, trauma is a leading cause of morbidity and mortality in the young and most active group of society. While specialist trauma…”
Get full text

102 Chemoimmunotherapy with Ofatumumab, Fludarabine and Cyclophosphamide (O-FC) in Previously Untreated Patients with Chronic Lymphocytic Leukemia by Wierda, William G, Kipps, Thomas J, Dürig, Jan, Griskevicius, Laimonas, Stilgenbauer, Stephan, Mayer, Jiří, Chan, Geoffrey, Gupta, Ira, Nielsen, Tina G, Russell, Charlotte A

Get full text